Posters

    Priming and Oxidative Burst Induction in Human Peripheral Blood Neutrophils by Treatment with Cigarette Smoke

    Friedrichs, B.; Neumann, U.; Schueller, J.
    Conference date
    Jun 30, 2010
    Conference name

    International Conference on Chronic Obstructive Pulmonary Disease
    Link to more information
    Topic
    Summary

    Neutrophils are front-line-defense cells of the innate immune system and a source of reactive oxygen species, inflammatory cytokines, lipid mediators, and tissue-damaging enzymes. They play important roles in both the goblet cell metaplasia in chronic bronchitis and the destruction of lung tissue in emphysema and thus are one of the primary effector cell types in COPD. In order to investigate the mechanism of neutrophil activation by cigarette smoke, neutrophils isolated from peripheral blood of human non-smokers were treated in vitro either directly with cigarette smoke-bubbled phosphate-buffered saline (SBPBS) or indirectly with supernatants from SBPBS-treated MonoMac-6 (mm6) cells. Readout parameters were changes in expression of the surface markers CD11B, CD66B, and CD62L; release of the granule proteins matrix metalloproteinase 9, matrix metalloproteinase 8, and lactoferrin; and oxidative burst induction as measured by n-formyl-methionyl-leucyl-phenylalanine-mediated superoxide release. Both direct and indirect treatment with SBPBS resulted in the priming of neutrophils as measured by an increase in CD11B and CD66B, a reduction in CD62L, and the release of granule proteins. An increase in the oxidative burst response was seen with indirect treatment only. Results suggest that cigarette smoking leads to continuous activation of neutrophils, which perpetuates the chronic lung inflammation seen in COPD patients. 

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.